Researcher profile · Semantic Scholar

J. Kuo

h-index: 9
Works: 21
Citations: 3,195

Most-cited papers

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
J. Canon, K. Rex, Anne Y. Saiki, C. Mohr +30 more
2019Nature1,980 citations
Semantic Scholar
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
D. Hong, M. Fakih, J. Strickler, J. Desai +30 more
2020New England Journal of Medicine867 citations Open access
Semantic Scholar
Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.
M. Fakih, B. O'Neil, T. Price, G. Falchook +8 more
2019Journal of Clinical Oncology130 citations
Semantic Scholar
Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review.
J. Kuo, L. Lilly, D. Hogg
2018Melanoma research61 citations
Semantic Scholar
Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients
B. Nguyen, J. Kuo, Anadian Budiman, H. Christie +1 more
2017Melanoma research58 citations
Semantic Scholar
CodeBreak 100: Phase I study of AMG 510, a novel KRASG12C inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
D. Hong, J. Kuo, A. Sacher, F. Barlesi +10 more
2020Journal of Clinical Oncology27 citations
Semantic Scholar
A randomized trial of the electronic Lung Cancer Symptom Scale for quality-of-life assessment in patients with advanced non-small-cell lung cancer.
J. Kuo, D. Graham, A. Salvarrey, F. Kassam +6 more
2019Current Oncology12 citations Open access
Semantic Scholar
Serious hepatic complications of selective internal radiation therapy with yttrium‐90 microsphere radioembolization for unresectable liver tumors
J. Kuo, Andrea Tazbirkova, Robert Allen, S. Kosmider +2 more
2014Asia-Pacific Journal of Clinical Oncology11 citations
Semantic Scholar
A Rapid Access Clinic to improve delivery of ambulatory care to cancer patients
J. Kuo, M. de Silva, Chandra Diwakarla, D. Yip
2017Asia-Pacific Journal of Clinical Oncology10 citations
Semantic Scholar
Immune checkpoint inhibitors in the treatment of advanced mucosal melanoma.
J. Kuo
2017Melanoma Management9 citations Open access
Semantic Scholar
A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer
Daphne Day, John J. Park, J. Coward, B. Markman +15 more
2023British Journal of Cancer8 citations Open access
Semantic Scholar
Administration of chemotherapy in patients on dialysis
J. Kuo, P. Craft
2015Anti-Cancer Drugs8 citations
Semantic Scholar
Combined cancer patient-reported symptom and health utility tool for routine clinical implementation: a real-world comparison of the ESAS and EQ-5D in multiple cancer sites.
M. Moskovitz, K. Jao, J. Su, M. Brown +13 more
2019Current Oncology6 citations Open access
Semantic Scholar
Application of hypersensitivity skin testing in chemotherapy-induced pneumonitis
J. Kuo, C. Hawkins, D. Yip
2015Asia Pacific Allergy5 citations Open access
Semantic Scholar
First-in-man trial of 4-(N-(S-penicillaminylacetyl)amino) phenylarsonous acid (PENAO) as a continuous intravenous infusion (CIVI), in patients (pt) with advanced solid tumours.
B. Tran, A. Hamilton, L. Horvath, Michael Lam +9 more
20164 citations
Semantic Scholar
FPT155-001: A phase Ia/Ib study of FPT155 (CD80-FC) in patients with advanced solid tumors.
M. Millward, Gan K. Hui, A. Joshua, J. Kuo +7 more
2019Journal of Clinical Oncology2 citations
Semantic Scholar
A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours
Sunit Sarkar, B. Tran, L. Horvath, Michael Lam +10 more
2021Cancer Chemotherapy and Pharmacology0 citations
Semantic Scholar
1057P Preliminary pharmacokinetics (PK), safety and efficacy of two dosing regimens of CS1003 (anti-PD-1) in solid tumours: 200 mg every 3-week (Q3W) and 400 mg every 6-week (Q6W) dosing
B. Markman, Daphne Day, J. Park, J. Coward +14 more
20200 citations Open access
Semantic Scholar
Response to osimertinib in EGF816-resistant T790M-mutated lung cancer
J. Kuo, N. Leighl
20180 citations
Semantic Scholar
Renal failure requiring hemodialysis in two patients with metastatic breast cancer treated with everolimus
J. Kuo, N. Gorddard, R. Stuart-Harris
20150 citations
Semantic Scholar
Access to ‘investigational’ cancer drugs: perspective of a trainee
J. Kuo
2015Internal medicine journal (Print)0 citations
Semantic Scholar

T. Price

×3

G. Falchook×3

R. Govindan×3

D. Yip×3

A. Prawira×3

L. Horvath×3

J. Canon×2

B. Houk×2